Mayne Pharma Group Limited (ASX: MYX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mayne Pharma Group Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mayne Pharma Group Limited (ASX: MYX)
Latest News
Share Market News
Leading broker names 2 shares to buy and 2 to sell
Share Market News
Federal Court approves Sirtex Medical Limited (ASX:SRX) takeover: Where I would reinvest these funds
Share Fallers
Why these 4 ASX shares have dropped lower today
Growth Shares
3 healthcare stars I want in my portfolio
Share Market News
Leading brokers name 3 ASX shares to buy today
Share Gainers
Why these 4 ASX shares are ending the week with a bang
Share Gainers
Mayne Pharma Group Ltd (ASX:MYX) shares rocket 14% higher on solid results
Share Market News
Earnings season week four preview
Share Market News
ALL ORDINARIES finishes lower Monday: 8 shares you missed
Healthcare Shares
Mayne Pharma Group Ltd (ASX:MYX) targets US growth with this US$30m acquisition
Share Gainers
Why these 4 ASX shares are starting the week on a high
Share Market News
Leading brokers name 3 ASX shares to buy today
Frequently Asked Questions
-
Mayne Pharma made a fully franked cash payment to shareholders in January 2023. Prior to that, the company’s last dividend payout was in 2011.
-
Mayne Pharma Group Ltd listed on the ASX on 29 June 2007.
MYX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Mayne Pharma Group Limited
Mayne Pharma Group Ltd (ASX: MYX) is a specialty pharmaceutical company focused on commercialising branded and generic pharmaceutical products. Its South Australian manufacturing base produces a portfolio of oral and topical products including tablets, powders, capsules, liquids, and creams.
Mayne Pharma performs limited research and development, typically acquiring off-patent or tail-end pharmaceutical brands. The company also has a contract manufacturing segment and advertises its services in assisting other drug developers in getting their products to market. The Group earns more than 90% of its revenue from the US market.
